Libertyville, IL, United States of America

Michael Michaelides

This inventor holds 32 USPTO granted patents and 10 published patent applications and 1 EPO patent. Top assignees: Abbott Laboratories Corporation, Abbvie Inc.. Active years: 1997-2018.

USPTO Granted Patents = 32 (Patent Applications = 10)

% Patents Active = 87.5

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 136(Granted Patents)

Location History:

Highland Park, IL (US) (1997)
Libertyville, IL (US) (2006 - 2018)

Company Filing History:

16 out of 4,186

Abbott Laboratories Corporation

Years Active: 1997-2018

Loading Chart...

Areas of Expertise:

NAMPT Inhibitors

ROCK Inhibitors

EED Inhibitors

CDK9 Kinase Inhibitors

Histone Methyltransferase G9a

Pyridazino Kinase Inhibitors

Indazole Kinase Inhibitors

Thieno Pyridine Kinase Inhibitors

Pyrrolopyridine Inhibitors

Protein Kinase Inhibitors

Isoindolinone Kinase Inhibitors

Tricyclic Pyrazole Kinase Inhibitors

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10093624 - NAMPT and ROCK inhibitors (2018-10-09),

2. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

3. 9796708 - Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors (2017-10-24),

4. 9302989 - NAMPT and rock inhibitors (2016-04-05),

5. 9284272 - Inhibitors of histone methyltransferase G9a (2016-03-15),

6. 9193723 - NAMPT inhibitors (2015-11-24),

7. 9187472 - NAMPT inhibitors (2015-11-17),

8. 9051327 - Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases (2015-06-09),

9. 8940778 - Indazole, benzisoxazole, and benzisothiazole kinase inhibitors (2015-01-27),

10. 8796289 - Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases (2014-08-05),

11. 8722890 - Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile (2014-05-13),

12. 8691810 - Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases (2014-04-08),

13. 8642776 - Indazole, benzisoxazole, and benzisothiazole kinase inhibitors (2014-02-04),

14. 8436179 - Kinase inhibitor with improved solubility profile (2013-05-07),

15. 8426408 - Pyrimidine inhibitors of kinases (2013-04-23),

Title: Innovations and Patents of Michael Michaelides

Introduction

Michael Michaelides, a prolific inventor based in Libertyville, IL, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 32 patents, he has dedicated his career to the development of innovative compounds that target critical biological processes.

Latest Patents

His recent patents include novel NAMPT and ROCK inhibitors. These patents disclose isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds designed to inhibit the activity of NAMPT and ROCK. The compounds, along with compositions containing them, offer methods for treating diseases characterized by the expression of NAMPT and ROCK. Additionally, Michaelides has developed indane inhibitors of EED, which includes compounds structured to combat various EED-related conditions, including cancer, through pharmaceutical compositions and methodologies.

Career Highlights

Michael Michaelides has built his career at notable companies such as Abbott Laboratories Corporation and AbbVie Inc. His work within these organizations has allowed him to advance his research and contribute meaningfully to the field of medical and pharmaceutical science.

Collaborations

Throughout his career, he has collaborated with esteemed colleagues, including Zhiqin Ji and Michael L. Curtin. These collaborations have facilitated the exchange of ideas and the development of innovative solutions in the realm of drug discovery and therapeutic interventions.

Conclusion

Michael Michaelides exemplifies dedication and innovation within the pharmaceutical industry. His extensive patent portfolio and collaborations highlight his commitment to advancing healthcare through the discovery and development of novel therapeutic compounds. As the landscape of medical science continues to evolve, the contributions of inventors like Michael are poised to play a pivotal role in shaping the future of treatment methodologies.